Trials / Completed
CompletedNCT02958436
A Study of Intravenously or Subcutaneously Administered REGN3500 in Healthy Adult Subjects
A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Intravenously or Subcutaneously Administered REGN3500 in Healthy Adult Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of this study is to evaluate the safety and tolerability of single ascending intravenous (IV) and subcutaneous (SC) doses of REGN3500 in healthy adult males and females
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | REGN3500 | |
| DRUG | Placebo |
Timeline
- Start date
- 2016-08-01
- Primary completion
- 2017-06-18
- Completion
- 2017-10-03
- First posted
- 2016-11-08
- Last updated
- 2017-11-08
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT02958436. Inclusion in this directory is not an endorsement.